2024
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyAnti-IL-17A antibodyAdverse eventsAnti-PD-1 antibody monotherapyInterleukin (IL)-17/IL-23 axisPsoriatic arthritisImmune checkpoint inhibitor treatmentPD-1 antibody therapyResponse to ICI therapyImmune-related adverse eventsIL-23/IL-17 axisImmune checkpoint inhibitor exposureIL-17/23 axisAnti-CTLA-4Checkpoint inhibitor therapyCell renal cell carcinomaAnti-IL-17AAnti-IL-23 antibodyAssociated with adverse eventsPre-existing psoriasisAnti-tumor efficacyIL-23/IL-17Renal cell carcinomaICI therapyAuthor Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitorsCancer therapyInflammatory arthritisTherapyCancerArthritis
2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsGround-glass opacitiesBlood biomarkersImmune checkpoint inhibitor pneumonitisCheckpoint inhibitor pneumonitisAcute myeloid leukemiaPost-test probabilityCheckpoint inhibitorsMyeloid leukemiaCT patternsLung inflammationPneumonitisInfected lungsRelevant blood biomarkersDiagnostic valueLung parenchymaPneumoniaCT imagesBloodBiomarkersPatientsHabitat imagesBlood modelDetection of pneumoniaLeukemiaLearning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune-related adverse eventsPre-existing autoimmune diseaseAutoimmune diseasesCheckpoint inhibitorsFlare-upBenefit of immune checkpoint inhibitorsAutoimmune disease flare-upManagement of flare-upsPre-existing autoimmune disordersImmune checkpoint inhibitor treatmentCancer CenterDisease flare-upContext of autoimmune diseasesAutoimmune disease progressionAutoimmune disease treatmentAutoimmune disordersAdverse eventsTreatment modificationOrgan damageComprehensive cancer centerDisease progressionPatientsCancerUS cancer centers
2022
Rheumatology (Arthritis and Myositis)
Kim S, Bowman S, Lu H. Rheumatology (Arthritis and Myositis). 2022, 301-313. DOI: 10.1007/978-3-031-00241-0_15.Peer-Reviewed Original ResearchImmune-related adverse eventsRheumatic immune-related adverse eventsImmune checkpoint inhibitorsAssociated with immune checkpoint inhibitorsDiscontinuation of immune checkpoint inhibitorsSystemic immune-related adverse eventsCourse of treatmentCheckpoint inhibitorsMyositis symptomsPersistent inflammatory arthritisComplete resolutionAdverse eventsRegistry studyInflammatory arthritisPrevalent typeMyositisPatientsArthritisArticularImmunosuppressionDMARDsArthralgiaMyalgiaPolymyalgiaPneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
Sheshadri A, Goizueta A, Shannon V, London D, Garcia‐Manero G, Kantarjian H, Ravandi‐Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Zarifa A, Albittar A, Zhong L, Akhmedzhanov F, Arain M, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza T, Godoy M, Shroff G, Kim S, Faiz S, Kontoyiannis D, Khawaja F, Jennings K, Daver N. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 2022, 128: 2736-2745. PMID: 35452134, PMCID: PMC9232977, DOI: 10.1002/cncr.34229.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute myeloid leukemiaImmune checkpoint inhibitor therapyAcute myeloid leukemia patientsICI-related pneumonitisPneumonitis riskMyeloid leukemiaCheckpoint inhibitorsEffect of immune checkpoint inhibitorsFemale sexReduced T-cell functionRisk factorsMultivariate Cox proportional hazards modelICI-containing regimensMultidisciplinary adjudication committeeRate of pneumonitisCheckpoint inhibitor therapyTreating acute myeloid leukemiaIncreased platelet countIncreased mortalityResponse to therapyT cell functionRetrospective cohort studyAttack cancer cellsCox proportional hazards modelsDistinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.Peer-Reviewed Original ResearchConceptsCD8+ T cellsImmune-related adverse eventsImmune checkpoint inhibitorsT cellsCheckpoint inhibitorsAssociated with immune-related adverse eventsPD-1 inhibitor therapyT-cell axisEnhanced Th17Antitumor immunityCTLA-4PD-1Inhibitor therapyImmunomodulatory therapyTCR repertoirePredictive biomarkersPeripheral bloodMyeloid cellsAdverse eventsCell signaturesCancer therapyInflammatory arthritisInflamed jointsTherapyTherapeutic target
2021
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis
Kim S, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor M. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021, 13: 465-475. PMID: 33641345, PMCID: PMC7983044, DOI: 10.2217/imt-2020-0272.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHistory of sarcoidosisPre-existing sarcoidosisCancer patientsCheckpoint inhibitorsRemote historyDose of atezolizumabEvaluate adverse eventsFrequency of flaresICI initiationHilar lymphadenopathySymptomatic exacerbationAdverse eventsSarcoidosisSubcutaneous nodulesPatientsFluctuating courseAtezolizumabCancerInhibitorsUveitisPrednisoneLymphadenopathyExacerbationDoseDistinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Frontiers In Immunology 2021, 11: 590494. PMID: 33552049, PMCID: PMC7859512, DOI: 10.3389/fimmu.2020.590494.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAML/MDS patientsPulmonary complicationsAcute myeloid leukemiaMDS patientsICI groupCheckpoint inhibitorsBronchoalveolar lavageMyelodysplastic syndromeT cellsTh17/Th1 cellsBAL T cellsRisk of pneumonitisBronchoalveolar lavage fluidFungal pneumoniaPulmonary symptomsIL-17Lavage fluidPeripheral bloodTh1 cellsLeukemia patientsMyeloid leukemiaDistinct immunophenotypePatientsComplications
2020
638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis
Abdel-Wahab N, Diab A, Katayama H, Kim S, Hanash S, Suarez-Almazor M. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a674-a674. DOI: 10.1136/jitc-2020-sitc2020.0638.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsRenal cell carcinomaNon-small cell lung carcinomaPlasma proteomic analysisStatistically significant differenceCheckpoint inhibitorsCell carcinomaAdverse eventsBiomarkers of immune-related adverse eventsDevelopment of immune-related adverse eventsPatients treated with immune checkpoint inhibitorsAnti-programmed cell death 1Immune checkpoint inhibitor initiationImmune checkpoint inhibitor treatmentResponse to ICI therapyNon-small cell lung cancerBlood drawThe University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterAnti-PD1 treatmentAnti-tumor immunityMD Anderson Cancer CenterCell death 1Inflammation of lung tissue657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma
Saberian C, Fa’ak F, Tayar J, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Ludford K, Johnson D, Abdel-Wahab N, Diab A. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: a394-a394. DOI: 10.1136/jitc-2020-sitc2020.0657.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIL-6R blockadeEfficacy of immune checkpoint inhibitorsMedian timeAdverse eventsIL-6RAnti-programmed cell death-1 antibodyImmune checkpoint inhibitor infusionsImmune mediated adverse eventsOverall tumor response ratePre-existing autoimmune diseaseInterleukin-6Interleukin-6 receptor blockadeClinical Disease Activity IndexICI-treated patientsTumor response rateMedian CRP levelsProspective clinical trialMinimal disease activityRelated adverse eventsDisease activity indexIrAE managementCheckpoint inhibitorsInterleukin-6 receptorMedian doseRS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.
Kim S, Murphy W, Aparicio A, Subudhi S. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal Of Immunotherapy And Precision Oncology 2020, 3: 128-132. PMID: 35663254, PMCID: PMC9165580, DOI: 10.36401/jipo-20-2.Peer-Reviewed Original ResearchSecond-generation hormone therapyImmune-related adverse eventsMetastatic prostate cancerImmune checkpoint inhibitorsProstate cancerHormone therapyCase of RS3PEPitting edemaRemitting seronegative symmetrical synovitisCycles of ipilimumabDiscontinued 2 monthsRadium-223 treatmentDiagnosis of RS3PEOptimal therapeutic strategyWeeks of treatmentCheckpoint inhibitorsAntitumor immunityRadium-223Bone scanInflammatory toxicityPredictive biomarkersIpilimumabActive inflammationSymmetrical synovitisAdverse events
2019
Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsNivolumab infusionAdverse eventsIL-17 producing CD4Immune checkpoint inhibitor therapyImmune checkpoint inhibitor treatmentImmune-related adverse eventsPatients treated with nivolumabCD4+ T cellsAmount of IL-17Characterized immune cellsCheckpoint inhibitor treatmentPD-1 inhibitorsCheckpoint inhibitor therapyCrystal arthritisSynovial fluidRenal cell carcinomaAutoimmune inflammatory arthritisT helper 17Neutrophil-driven inflammationProphylactic colchicinePD-1Inhibitor therapyConclusionsThis case
2018
Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists
Kim S, Suarez-Almazor M. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Review Of Clinical Immunology 2018, 15: 211-213. PMID: 30589372, DOI: 10.1080/1744666x.2019.1559731.Peer-Reviewed Original Research
2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCheckpoint inhibitorsReceptor antibodiesAssociated with immune-related adverse eventsMild immune-related adverse eventsEffective alternative to corticosteroidsEfficacy of ICI therapyICI-induced inflammatory arthritisImmune checkpoint inhibitor therapyAnti-IL-6 receptor antibodyAlternative to corticosteroidsTreated with corticosteroidsTreated with tocilizumabTumor necrosis factor-aImmune dampening effectsInflammatory side effectsAlternative therapeutic strategiesFood and Drug AdministrationTreatment of rheumatoid arthritisJuvenile idiopathic arthritisAntitumour responseICI therapyTNFa inhibitorsCheckpoint inhibition